TORONTO, Nov. 2, 2015 (GLOBE NEWSWIRE) -- Profound Medical Corp. ("Profound" or "Company") (TSXV:PRN), a medical device company developing and commercializing a unique, minimally invasive treatment to ablate the prostate gland in prostate cancer patients, today announced that Hartmut Warnken will join the Company in the role of Vice President, International Sales.
Mr. Warnken is a senior manager with proven success in sales and marketing within the medical technology industry. Mr. Warnken was most recently Vice President & General Manager Europe, Middle East, Japan and Asia Pacific, Managing Director/Officer for IMRIS Pte. Ltd., IMRIS Germany GmbH and IMRIS KK Japan. Prior to his 6 years at IMRIS, Mr. Warnken was with BrainLAB for 7 years, his most recent position being that of Division Director Integrated Operating Room Solutions. He holds an MBA from ESCP-Europe Business School and a M.Eng. from Augsburg College.
Mr. Warnken will report to Steve Plymale, CEO and will lead the development and design of the sales strategy and communicate the vision to reach revenue growth goals.
"We are very pleased to welcome Hartmut to the Profound Medical team. His depth of knowledge in managing entire business operations will ensure his success in building and managing Profound Medical's International Sales Team," said Steve Plymale, CEO, Profound Medical Corp. "With our anticipated foray into the European market in 2016, Hartmut is poised to provide the medical community and patients with what we believe to be the new standard of care for localized prostate cancer."
About Profound Medical Corp.
Profound Medical is a Canadian medical device company that has developed a unique and minimally invasive treatment to ablate prostate tissue in patients with prostate cancer. Profound's novel technology combines real-time MR imaging with transurethral therapeutic ultrasound and closed-loop thermal feedback control. It provides a highly precise treatment tailored to patient-specific anatomy and pathology. This method of prostate ablation offers short treatment times and low morbidity, allowing for fast patient recovery. The potential of this technology is currently being demonstrated in clinical trials. For more information, visit profoundmedical.com
Notice regarding forward-looking statements:
This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound's technology in the treatment of prostate cancer. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the pharmaceutical industry, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.